at this time. they have about 50M in their coffer! are they worried about negative Adcom?
sucks, the $4.40 will be the cap for a while.
The prostate cancer drug shows promise but since it is a very slow growing cancer the phase 3 trials take a very long time to compete and a company needs at least a 2-3 year supply of money to complete the trial and get to the FDA approval.
A very smart move if capital starts to dry up in a negatively trending market